Exeliom Biosciences key facts
as of Oct 2026- Developer of immunotherapies designed to help harness the therapeutic potential of gut microbiota.
- Exeliom Biosciences is valued at approximately $7.4M as of Oct 2026 (last reported valuation).
- It has raised $33.3M; the latest was Later Stage VC ($3.3M) in Oct 2025.
- Notable investors include Bpifrance, European Innovation Council, UI Investissement, Elaia Partners, CE-Ventures — 19 tracked in total.
- Status: Privately Held (backing).
Exeliom Biosciences's last reported valuation, Dec 2018. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch Exeliom Biosciences: the Monday email on marks, rounds and moves
Exeliom Biosciences funding rounds
No funding rounds for Exeliom Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Exeliom Biosciences
19+Exeliom Biosciences valuation
Exeliom Biosciences's last reported valuation was $7.4 million in Dec 2018. No priced round, secondary trade or fund mark has surfaced since.
Exeliom Biosciences investors
19 investors are on record for Exeliom Biosciences, including Bpifrance, European Innovation Council, UI Investissement and Elaia Partners.
About Exeliom Biosciences
Developer of immunotherapies designed to help harness the therapeutic potential of gut microbiota. The company develops single bacterial strain drug candidates to deliver microbiome-based immunotherapy for treating inflammatory bowel diseases and cancer, starting with Crohn's Disease as a first indication, enabling patients to lead longer and healthier lives by accessing their medicines derived from microbiota.
- Sector
- Healthcare
- HQ
- Dijon, France
- Founded
- 2016
- Employees
- 8
- Website
- exeliombio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.